Computational assessment of saikosaponins as adjuvant treatment for COVID-19: molecular docking, dynamics, and network pharmacology analysis
Tóm tắt
Saikosaponins are major biologically active triterpenoids, usually as glucosides, isolated from Traditional Chinese Medicines (TCM) such as Bupleurum spp., Heteromorpha spp., and Scrophularia scorodonia with their antiviral and immunomodulatory potential. This investigation presents molecular docking, molecular dynamics simulation, and free energy calculation studies of saikosaponins as adjuvant therapy in the treatment for COVID19. Molecular docking studies for 23 saikosaponins on the crystal structures of the extracellular domains of human lnterleukin-6 receptor (IL6), human Janus Kinase-3 (JAK3), and dehydrogenase domain of Cylindrospermum stagnale NADPH–oxidase 5 (NOX5) were performed, and selected protein–ligand complexes were subjected to 100 ns molecular dynamics simulations. The molecular dynamics trajectories were subjected to free energy calculation by the MM-GBSA method. Molecular docking and molecular dynamics simulation studies revealed that IL6 in complex with Saikosaponin_U and Saikosaponin_V, JAK3 in complex with Saikosaponin_B4 and Saikosaponin_I, and NOX5 in complex with Saikosaponin_BK1 and Saikosaponin_C have good docking and molecular dynamics profiles. However, the Janus Kinase-3 is the best interacting partner for the saikosaponin compounds. The network pharmacology analysis suggests saikosaponins interact with the proteins CAT Gene CAT (Catalase) and Checkpoint kinase 1 (CHEK1); both of these enzymes play a major role in cell homeostasis and DNA damage during infection, suggesting a possible improvement in immune response toward COVID-19.
Tài liệu tham khảo
Stower H (2020) Spread of SARS-CoV-2. Nat Med 26:465–465. https://doi.org/10.1038/s41591-020-0850-3
Ou X, Liu Y, Lei X et al (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11:1–12. https://doi.org/10.1038/s41467-020-15562-9
Santibáñez-Morán MG, López-López E, Prieto-Martínez FD, Sánchez-Cruz N, Medina-Franco JL (2020) Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease. RSC Adv 10(42):25089–25099. https://doi.org/10.1039/d0ra04922k
Cheng H, Wang Y, Wang G (2020) Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol 92:726–730. https://doi.org/10.1002/jmv.25785
Watanabe T, Jono H, Han J et al (2004) Synergistic activation of NF-B by nontypeable Haemophilus influenzae and tumor necrosis factor. Proc Natl Acad Sci 101:3563–3568. https://doi.org/10.1073/pnas.0400557101
López-López E, Barrientos-Salcedo C, Prieto-Martínez FD, Medina-Franco JL (2020) In silico tools to study molecular targets of neglected diseases: inhibition of TcSir2rp3, an epigenetic enzyme of Trypanosoma cruzi. Adv Protein Chem Struct Biol. https://doi.org/10.1016/bs.apcsb.2020.04.001
Prieto-Martínez FD, López-López E, Eurídice Juárez-Mercado K, Medina-Franco JL (2019) Computational drug design methods—current and future perspectives. In: In silico drug design, pp 19–44. https://doi.org/10.1016/b978-0-12-816125-8.00002-x
Li X, Li X, Huang N et al (2018) A comprehensive review and perspectives on pharmacology and toxicology of saikosaponins. Phytomedicine 50:73–87. https://doi.org/10.1016/j.phymed.2018.09.174
Li X-Q, Song Y-N, Wang S-J et al (2018) Saikosaponins: a review of pharmacological effects. J Asian Nat Prod Res 20:399–411. https://doi.org/10.1080/10286020.2018.1465937
Cheng P-W, Ng L-T, Chiang L-C, Lin C-C (2006) Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin Exp Pharmacol Physiol 33:612–616. https://doi.org/10.1111/j.1440-1681.2006.04415.x
Ashour ML, Wink M (2011) Genus Bupleurum: a review of its phytochemistry, pharmacology and modes of action. J Pharm Pharmacol 63:305–321. https://doi.org/10.1111/j.2042-7158.2010.01170.x
Pistelli L, Bilia AR, Marsili A et al (1993) Triterpenoid saponins from Bupleurum fruticosum. J Nat Prod 56:240–244. https://doi.org/10.1021/np50092a009
Chen J, Duan M, Zhao Y et al (2015) Saikosaponin A inhibits influenza A virus replication and lung immunopathology. Oncotarget 6:42541–42556. https://doi.org/10.18632/oncotarget.6448
Lin C-W, Tsai F-J, Tsai C-H et al (2005) Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res 68:36–42. https://doi.org/10.1016/j.antiviral.2005.07.002
Sinha SK, Prasad SK, Islam MA et al (2020) Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1779132
Sinha SK, Shakya A, Prasad SK et al (2020) An in silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1762741
Chikhale RV, Sinha SK, Patil RB, Prasad SK, Shakya A, Gurav N et al (2020) In silico investigation of phytochemicals from Asparagus racemosus as plausible antiviral agent in COVID-19. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1784289
Chikhale RV, Gurav SS, Patil RB, Sinha SK, Prasad SK, Shakya A et al (2020) Sars-CoV-2 host entry and replication inhibitors from Indian ginseng: an in silico approach. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1778539
Lagunin A, Ivanov S, Rudik A et al (2013) DIGEP-Pred: web service for in silico prediction of drug-induced gene expression profiles based on structural formula. Bioinformatics 29:2062–2063. https://doi.org/10.1093/bioinformatics/btt322
Szklarczyk D, Gable AL, Lyon D et al (2019) STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47:D607–D613. https://doi.org/10.1093/nar/gky1131
Bazan JF (1990) Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci 87:6934–6938. https://doi.org/10.1073/pnas.87.18.6934
Varghese JN, Moritz RL, Lou M-Z et al (2002) Structure of the extracellular domains of the human interleukin-6 receptor α-chain. Proc Natl Acad Sci 99:15959–15964. https://doi.org/10.1073/pnas.232432399
Hui DS, Wong GW (2004) Advancements in the battle against severe acute respiratory syndrome. Expert Opin Pharmacother 5:1687–1693. https://doi.org/10.1517/14656566.5.8.1687
Fu Y, Cheng Y, Wu Y (2020) Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin 35:266–271. https://doi.org/10.1007/s12250-020-00207-4
Jin Y, Yang H, Ji W et al (2020) Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 12:372. https://doi.org/10.3390/v12040372
Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK (2020) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 34:327–331. https://doi.org/10.23812/CONTI-E
Siddiqi HK, Mehra MR (2020) COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal. J Heart Lung Transplant 39:405–407. https://doi.org/10.1016/j.healun.2020.03.012
O’Shea JJ, Schwartz DM, Villarino AV et al (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311–328. https://doi.org/10.1146/annurev-med-051113-024537
Benveniste EN, Liu Y, McFarland BC, Qin H (2014) Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis. J Interferon Cytokine Res 34:577–588. https://doi.org/10.1089/jir.2014.0012
Xin P, Xu X, Deng C et al (2020) The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol 80:106210. https://doi.org/10.1016/j.intimp.2020.106210
Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. Curr Biol 24:R453–R462. https://doi.org/10.1016/j.cub.2014.03.034
Drummond GR, Selemidis S, Griendling KK, Sobey CG (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10:453–471. https://doi.org/10.1038/nrd3403
Finegold AA, Shatwell KP, Segal AW et al (1996) Intramembrane bis-heme motif for transmembrane electron transport conserved in a yeast iron reductase and the human NADPH oxidase. J Biol Chem 271:31021–31024. https://doi.org/10.1074/jbc.271.49.31021
Magnani F, Nenci S, Millana Fananas E et al (2017) Crystal structures and atomic model of NADPH oxidase. Proc Natl Acad Sci. https://doi.org/10.1073/pnas.1702293114
Kerzare D, Chikhale R, Bansode R et al (2016) Design, synthesis, pharmacological evaluation and molecular docking studies of substituted oxadiazolyl-2-oxoindolinylidene propane hydrazide derivatives. J Braz Chem Soc. https://doi.org/10.5935/0103-5053.20160090
Pant AM, Chikhale RV, Menghani SS, Khedekar PB (2014) LEDGF/p75 IN interaction inhibitors: in silico studies of an old target with novel approach. BMC Infect Dis. https://doi.org/10.1186/1471-2334-14-s3-p18
Li S, Zhang Y, Guan Z et al (2020) SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Sig Transduct Target Ther 5:235. https://doi.org/10.1038/s41392-020-00334-0
Khanal P, Duyu T, Patil BM, Dey YN, Pasha I, Wanjari M, Gurav SS, Maity A (2020) Network pharmacology of AYUSH recommended immune-boosting medicinal plants against COVID-19. J Ayurveda Integr Med. https://doi.org/10.1016/j.jaim.2020.11.004
Khanal P, Patil BM, Chand J et al (2020) Anthraquinone derivatives as an immune booster and their therapeutic option against COVID-19. Nat Prod Bioprospect 10:325–335. https://doi.org/10.1007/s13659-020-00260-2
Saleh J, Peyssonnaux C, Singh KK, Edeas M (2020) Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. Mitochondrion. https://doi.org/10.1016/j.mito.2020.06.008
Wickramarachchi DC, Theofilopoulos AN, Kono DH (2010) Immune pathology associated with altered actin cytoskeleton regulation. Autoimmunity 43(1):64–75. https://doi.org/10.3109/08916930903374634
Ansel KM (2013) RNA regulation of the immune system. Immunol Rev 253:5–11. https://doi.org/10.1111/imr.12062
Weichhart T, Säemann MD (2008) The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis 67:iii70–iii74
Reinstein E (2004) Immunologic aspects of protein degradation by the ubiquitin-proteasome system. Isr Med Assoc J 6(7):420–424
Han JM, Patterson SJ, Levings MK (2012) The role of the PI3K signaling pathway in CD4+ T cell differentiation and function. Front Immunol 3:245. https://doi.org/10.3389/fimmu.2012.00245
Batlle E, Massagué J (2019) Transforming growth factor-β signaling in immunity and cancer. Immunity 50(4):924–940. https://doi.org/10.1016/j.immuni.2019.03.024
Shuai K, Liu B (2003) Regulation of JAK–STAT signalling in the immune system. Nature Rev Immunol 3(11):900–911. https://doi.org/10.1038/nri1226
Vig M, Kinet J-P (2009) Calcium signaling in immune cells. Nature Immunol 10(1):21–27. https://doi.org/10.1038/ni.f.220
Šedý J, Bekiaris V, Ware CF (2014) Tumor necrosis factor superfamily in innate immunity and inflammation. Cold Spring Harbor Perspect Biol 7(4):a016279
Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, Freund C (2017) Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol 8:292
Gil D, Rodriguez J, Ward B et al (2017) Antioxidant activity of SOD and catalase conjugated with nanocrystalline ceria. Bioeng Basel Switz. https://doi.org/10.3390/bioengineering4010018
Li Z, Ju X, Silveira PA et al (2019) CD83: Activation marker for antigen presenting cells and its therapeutic potential. Front Immunol 10:1312. https://doi.org/10.3389/fimmu.2019.01312
Grosche L, Knippertz I, König C et al (2020) The CD83 molecule—an important immune checkpoint. Front Immunol. https://doi.org/10.3389/fimmu.2020.00721
Patil M, Pabla N, Dong Z (2013) Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell Mol Life Sci 70:4009–4021. https://doi.org/10.1007/s00018-013-1307-3
Zhou J, Zheng X, Shen H (2012) Targeting RNA-splicing for SMA treatment. Mol Cells 33:223–228. https://doi.org/10.1007/s10059-012-0005-6
Cano RLE, Lopera HDE (2013) Introduction to T and B lymphocytes. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A et al (eds) Autoimmunity: from bench to bedside. El Rosario University Press, Bogota
Nandi A, Yan L-J, Jana CK, Das N (2019) Role of catalase in oxidative stress- and age-associated degenerative diseases. Oxid Med Cellul Longev 2019:1–19. https://doi.org/10.1155/2019/9613090
Chen Z, John Wherry E (2020) T cell responses in patients with COVID-19. Nature Rev Immunol. https://doi.org/10.1038/s41577-020-0402-6
Guerra B, Issinger O-G, Wang JY (2003) Modulation of human checkpoint kinase Chk1 by the regulatory β-subunit of protein kinase CK2. Oncogene 22(32):4933–4942